Mary R. Gates

发表

Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans

E. Choo, C. Hop, J. Halladay, 2016, Drug Metabolism and Disposition.

Application of a Novel ‘Make and Test in Parallel’ Strategy to Investigate the Effect of Formulation on the Pharmacokinetics of GDC-0810 in Healthy Subjects

S. Girish, S. Sahasranaman, Buyun Chen, 2018, Pharmaceutical Research.

A first-in-human phase Ib study to evaluate the MEK inhibitor GDC-0973, combined with the pan-PI3K inhibitor GDC-0941, in patients with advanced solid tumors.

M. Belvin, G. Shapiro, P. LoRusso, 2012 .

A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer.

Sung-Bae Kim, S. Loi, A. Bardia, 2020 .

Effect of OATP1B1/1B3 Inhibitor GDC‐0810 on the Pharmacokinetics of Pravastatin and Coproporphyrin I/III in Healthy Female Subjects

J. Ware, E. Choo, Kenta Yoshida, 2018, Journal of clinical pharmacology.

Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors

Suzanne F. Jones, C. Rudin, G. Shapiro, 2019, Investigational New Drugs.

Safety and activity of single-agent giredestrant (GDC-9545) from a phase Ia/b study in patients (pts) with estrogen receptor-positive (ER+), HER2-negative locally advanced/metastatic breast cancer (LA/mBC).

E. L. Miranda, S. Loi, A. Bardia, 2021 .

Abstract LB-89: Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: A first-in-human phase Ib study in patients with advanced solid tumors

M. Belvin, G. Shapiro, P. LoRusso, 2011 .

Evaluation of pharmacodynamic (PD) and biologic activity in a preoperative window-of-opportunity (WOO) study of giredestrant (GDC-9545) in postmenopausal patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2–) operable breast cancer (BC).

Leonard D. Goldstein, A. Bardia, P. Kabos, 2021 .

Abstract B75: A first in-human phase I study to evaluate the MEK1/2 inhibitor GDC-0623 in patients with advanced solid tumors.

A. El-Khoueiry, J. Bendell, I. Chang, 2013 .

Abstract 4716: A first-in-human phase 1 study to evaluate the MEK1/2 inhibitor GDC-0973 administered daily in patients with advanced solid tumors

B. Sikic, P. LoRusso, W. Ma, 2011 .

C ] Cobimetinib , a MEK Inhibitor , in Humans

Isabelle, E. Choo, C. Hop, 2015 .

Abstract PD7-05: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-9545, in postmenopausal women with estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer

E. Winer, S. Loi, A. Bardia, 2020, Poster Spotlight Session Abstracts.

Abstract PD5-10: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-0927, in postmenopausal women with estrogen receptor positive (ER+) HER2-negative metastatic breast cancer (BC)

A. Bardia, J. Spoerke, J. Giltnane, 2018 .